EPO (epoetin): approved uses, research, side effects and doping

In short

EPO, or erythropoietin, is a hormone made by the kidneys that regulates red blood cell production, and the epoetins used as medicines are prescription medicines with an EU marketing authorisation, for example for anaemia caused by kidney disease or cancer treatment [1]regulator [2]official. In well-trained cyclists EPO improved a laboratory maximal test but not a race-like climb [7]A.

• In treatment, epoetin is used for symptomatic anaemia caused by kidney failure and chemotherapy, for certain bone marrow diseases, and before major surgery [2]official.
• There is strong evidence on harms: in kidney patients, aiming for a higher haemoglobin target increased strokes, high blood pressure and clotting of dialysis access [14]A, and in cancer patients mortality rose [15]A.
• In a trial of 48 well-trained cyclists, EPO raised haemoglobin and maximal power, but a long exercise test and a climb up Mont Ventoux were not faster [7]A. In another 48-person trial small doses improved a time trial by 4.1% [25]A.
• In Finland the epoetins are on the medicines list, and their EU marketing authorisations are also valid in Finland [3, 4]regulator. WADA prohibits EPO in sport at all times (class S2.1) [5]regulator.

What is EPO?

EPO, or erythropoietin, is the body's own hormone that regulates red blood cell production. According to the product information it is a glycoprotein hormone produced mainly by the kidneys when oxygen in the tissues falls [2]official.

The medicines are epoetins. For example, epoetin alfa is made with recombinant DNA technology in Chinese hamster ovary cells, and its sequence of 165 amino acids is the same as that of human urinary EPO [2]official. According to the EMA it works in the same way as the body's own hormone [1]regulator. EPO is a protein, not a short peptide.

The medicines list includes epoetin alfa, epoetin zeta, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta [4]regulator. Basics: What are peptides?. All substances: Peptides A-Z.

Evidence at a glance

Each cell gives the kind of study and its source. The letter is the evidence level, not the result.

"-" = such studies are not covered on this page, because human studies are plentiful.

What is EPO used for?

EPO is used to treat anaemia and reduce the need for blood transfusions. The approved indications of Binocrit (epoetin alfa) are [2]official:

• Symptomatic anaemia of chronic kidney failure in adults and in children on dialysis, and in adults not yet on dialysis [2]official.
• Anaemia from chemotherapy in adults with solid tumours, lymphoma or myeloma who are at risk of transfusion [2]official.
• Around surgery: to collect the patient's own blood before major surgery, and to reduce transfusions of donor blood before major orthopaedic surgery when anaemia is moderate [2]official.
• Myelodysplastic syndrome (a bone marrow disease), when the risk is low or intermediate and the body's own EPO level is low [2]official.

According to the EMA, the medicine is available only on prescription, and treatment is started under the supervision of a doctor experienced in these conditions. The patient's iron stores are checked and iron given if needed. The medicine is injected into a vein or under the skin depending on the indication, and injections under the skin can be given by the patient or a carer after training [1]regulator.

Not an approved use. Improving endurance is not an approved indication [2]official. According to a review, using EPO to enhance performance in cycling is very common [8].

How does EPO work?

EPO increases red blood cell production in the bone marrow. According to the product information it binds to a receptor on the surface of red blood cell precursors, blocks their programmed cell death and speeds up their multiplication [2]official. New red cells reach the blood with a delay: in chemotherapy the product information advises taking a 2-3 week delay into account [2]official.

EPO receptors may also be present on many kinds of tumour cells. According to the product information, as with all growth factors there is a concern that epoetins could stimulate tumour growth [2]official.

In an animal study, EPO receptors were seen in abundance on brain capillaries, and in rodents EPO given into the circulation reduced experimental brain damage [19]C. According to a review, the red cell and tissue-protection effects run through different receptors, and on the basis of this difference EPO-derived substances such as ARA-290 have been developed [23].

Has EPO been studied in humans?

Yes, extensively. There are large randomised trials and meta-analyses in kidney and cancer patients [11, 12, 13, 14, 15]A, and also a placebo-controlled trial in healthy cyclists [7]A. Many trials have shown harms or no benefit.

Anaemia of kidney disease

• High or lower haemoglobin target (2006). In an open-label trial of 1,432 kidney patients, epoetin alfa was given to target haemoglobin of 13.5 or 11.3 g/dl. The higher-target group had more deaths, heart attacks, hospital stays for heart failure and strokes (hazard ratio 1.34), and quality of life did not improve more [11]A.
• Full correction of anaemia (2006). In a three-year trial of 603 patients, aiming for normal haemoglobin did not reduce cardiovascular events. General health and physical function improved, but more patients needed dialysis (127 vs 111) [12]A.
• Darbepoetin in people with diabetes (2009). In 4,038 patients with type 2 diabetes, kidney disease and anaemia, darbepoetin did not reduce the risk of death or a cardiovascular event, or of death or end-stage kidney disease, but strokes were almost twice as common (101 vs 53). Fewer transfusions were needed [13]A.
• Meta-analysis (2010). In 27 trials (10,452 patients), a higher haemoglobin target increased the risk of stroke, high blood pressure and clotting of dialysis access. The difference in mortality was not statistically significant, but according to the authors a higher target probably also increases mortality [14]A.

Cancer patients

In a meta-analysis of 53 trials (13,933 cancer patients), drugs that stimulate red cell production increased mortality during the treatment period (hazard ratio 1.17) and worsened overall survival. According to the authors, the increased risk of death must be weighed against the benefits [15]A. According to the product information, blood transfusion may be the preferred treatment for anaemia in cancer patients in some situations [2]official.

Other uses where no benefit was found

• Heart failure (2013). In 2,278 patients darbepoetin did not reduce deaths or hospital stays for heart failure, but thromboembolic events were more common (13.5% vs 10.0%) [20]A.
• Heart attack (2011). In 222 heart attack patients, a single dose of epoetin alfa into a vein after balloon angioplasty did not reduce infarct size. Death, a new heart attack, stroke or stent thrombosis occurred in 5 of 125 patients on epoetin but in none of 97 on placebo, and in those aged 70 or over the infarct was larger [26]A.
• Intensive care (2007). In 1,460 intensive care patients, epoetin alfa did not reduce transfusions, but clots were more common. In trauma patients mortality was lower in a prespecified analysis, which according to the authors suggests a possible benefit in this group [21]A.
• Stroke (2009). In a trial of 522 patients, EPO did not improve recovery, and mortality was 16.4% with EPO and 9.0% with placebo. According to the authors, the trial was negative and raised safety concerns, especially in patients who had clot-dissolving treatment [17]A.
• Preterm babies (2020). 941 extremely preterm babies received EPO or placebo. There was no difference in death or severe developmental impairment at two years (26% in both groups) [18]A.

Animal studies: the promise of nerve protection

In rodents, EPO given into the circulation reduced brain damage by about 50-75% when given before a local disruption of brain blood flow or up to six hours after it. In the same work EPO also lessened concussive brain injury, the immune damage in a model of experimental multiple sclerosis and the effect of a nerve toxin, and the authors proposed human trials [19]C.

The promise was not repeated in humans: the stroke trial showed no benefit [17]A, and the preterm trial found no difference [18]A. This is therefore not presented in a "Promising, but so far only in animals" section on this page: there are already negative human trials for the same outcome.

Healthy people and athletes

• Cyclists (2017). 48 well-trained but non-professional male cyclists received EPO or placebo for eight weeks. EPO raised haemoglobin, maximal power and maximum oxygen uptake in a laboratory test, but a 45-minute exercise test and a climb up Mont Ventoux did not differ between groups (1 h 40 min 32 s vs 1 h 40 min 15 s). All adverse events were mild or moderate and similar in both groups [7]A.
• Small doses (2023). 48 healthy recreational to trained people (24 men and 24 women) received small doses of EPO or saline into a vein for four weeks. In the EPO group time trial mean power improved by 4.1%, peak oxygen uptake by 4.2% and total haemoglobin mass by 6.7%; there were no changes in the placebo group [25]A.
• Healthy non-athletes (2007). In an eight-person study, EPO raised maximum oxygen uptake by about 12% and increased time to exhaustion in hard exercise by about 54% [9]B.
• Reviews. According to a 2013 review, there is no scientific basis for a performance-enhancing effect of EPO in elite cyclists, and harms have not been studied adequately in this group [8]. According to a 2018 review, maximum oxygen uptake and maximal power rose in the studies, but few reported better performance, and the effect of small doses on endurance is unclear [10].

Who studies EPO?

The effect of EPO on performance and the accuracy of doping tests have been studied by the Centre for Human Drug Research in Leiden, the Netherlands [7, 22]A. The data of the cancer meta-analysis were analysed by independent statisticians, and funders included the German Federal Ministry of Education and Research [15]A.

The preterm trial was funded by the US National Institute of Neurological Disorders and Stroke (NINDS) [18]A, and the heart failure trial by the drug company Amgen [20]A. The stroke trial was a German multicentre trial [17]A.

Author of this page: editorial team

This page was written by the Molecular Recovery editorial team. The draft was produced with AI assistance, and the claims were checked against the sources (AI policy). The page has not been medically reviewed. How we work: About us.

How long does EPO stay in the body?

Epoetin alfa stays in the blood for hours, but new red cells appear only after a delay of weeks [2]official. According to the product information its half-life in healthy people is about 4 hours after injection into a vein and an estimated 24 hours after injection under the skin. In kidney patients the half-life after injection into a vein is slightly longer, about 5 hours [2]official.

After injection under the skin the level peaks after 12-18 hours, and in healthy people about 20% reaches the circulation [2]official.

In the cyclist study, urine tests detected use best 2-6 days after dosing, and sensitivity fell quickly after that [22]A.

What are the side effects of EPO?

The main harms of EPO are a rise in blood pressure and blood clots. According to the product information, the most common adverse reaction is a dose-dependent rise in blood pressure or worsening of existing high blood pressure [2]official. More: Side effects and safety.

Side effects in the product information

• Very common: diarrhoea, nausea, vomiting and fever. Flu-like symptoms may occur especially at the start of treatment [2]official [1]regulator.
• Common: headache, high blood pressure, venous and arterial clots, cough, rash, joint, bone and muscle pain, and injection site reactions [2]official.
• Blood clots: more clots have been seen with drugs that stimulate red cell production, such as deep vein thrombosis, pulmonary embolism, heart attacks and strokes, some of them fatal [2]official.
• Hypertensive crisis and seizures: hypertensive crisis with brain symptoms and seizures has occurred even in patients whose blood pressure was previously normal or low. A sudden stabbing migraine-like headache may be a warning sign [2]official.
• Severe skin reactions: Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported, more severe with long-acting epoetins [2]official.

Pure red cell aplasia

A rare but serious harm is antibody-mediated pure red cell aplasia, in which the bone marrow stops making red cells. Over three years, 13 kidney patients were identified, all with antibodies that neutralised EPO; antibody levels fell slowly after epoetin was stopped [16]B. According to the product information, cases have been reported very rarely, more often with injection under the skin than into a vein, and the patient must not be given any other EPO product afterwards [2]official.

Haemoglobin too high

In kidney patients, aiming for higher haemoglobin increased strokes, high blood pressure and clotting of dialysis access [14]A, and darbepoetin almost doubled strokes in people with diabetes [13]A. According to the product information, controlled trials have not shown significant benefit when haemoglobin is raised above the level needed to control symptoms [2]official.

Cancer patients

According to the product information, in controlled trials epoetin alfa and similar drugs were associated with poorer local tumour control or shorter survival, for example in head and neck cancer and breast cancer [2]official. In the meta-analysis mortality rose during treatment [15]A.

Healthy people

No serious adverse events were seen over eight weeks in the cyclist trial [7]A, but a 48-person trial is too small to judge rare harms. According to a review, harms have not been studied adequately in athletes, but they appear worrying [8].

Interactions and who lacks data

According to the product information, there is no evidence that epoetin alfa alters the metabolism of other medicines. Medicines that reduce red cell production may weaken its effect. Ciclosporin levels are monitored, because ciclosporin binds to red cells [2]official.

Epoetin alfa must not be used if blood pressure is not controlled, if the patient has developed pure red cell aplasia after any EPO treatment, or in a surgical patient who cannot receive clot-preventing treatment. Caution is needed in epilepsy, liver failure and porphyria. According to the product information, safety in liver dysfunction has not been established [2]official.

Evidence against and what we do not know

EPO reliably raises haemoglobin, but in large trials raising haemoglobin often did not improve patients' outcomes and increased harms [11, 13, 14, 15]A.

Contrary evidence

• In cyclists the laboratory maximal test improved, but long exercise and a race-like climb did not [7]A.
• In rodents EPO protected the brain [19]C, but in a human stroke trial there was no benefit and mortality was higher [17]A, and no difference was found in preterm babies [18]A.
• In heart attack, infarct size was not reduced and adverse events were more common [26]A.
• In heart failure [20]A, intensive care [21]A and diabetic kidney disease [13]A, large trials found no benefit for the main outcomes.
• Aiming for normal haemoglobin did not reduce cardiac events in kidney patients [12]A.

What the evidence does not support

• "A better laboratory test translates directly to competition": in a trial of 48 cyclists the maximal test improved but the mountain climb did not [7]A. In another trial small doses improved a time trial [25]A, so the evidence is conflicting, and according to a review there is no evidence in elite cyclists [8].
• "More haemoglobin is always better": in kidney patients a higher target increased harms without extra benefit to quality of life [11, 14]A.
• "EPO protects the brain": the promise of animal studies was not repeated in stroke or in preterm babies [17, 18]A.

What is not known

• How the results translate to competition. According to a 2018 review the effect of small doses was unclear [10], in a 2023 trial the time trial improved [25]A, but there was no difference in the mountain climb [7]A. Studies are few and small.
• The true rate of harms in healthy people and athletes, because the studies are small and short [7]A [8].
• Why a higher haemoglobin target increases harms. According to the meta-analysis authors the mechanism is unclear [14]A.
• Whether trauma patients in intensive care benefit. Mortality was lower in a prespecified subgroup, but the result needs confirmation [21]A.

EPO dosing

EPO is a prescription medicine, so this site has no dose page or calculator for it. The treating doctor decides the dose according to the product's approved information [2]official.

According to the EMA, the dose, injection interval and length of treatment depend on the indication and the patient's body weight, and they are adjusted according to response. In kidney, myelodysplasia and cancer patients haemoglobin is kept within the recommended range, and the lowest dose that controls symptoms is used [1]regulator.

What the studies cannot tell you. The amounts used in trials were chosen for the study design and are not recommendations. According to the product information, high cumulative epoetin doses may be associated with a higher risk of death and cardiovascular and cerebrovascular events in kidney patients [2]official.

EPO vs ARA-290: what is the difference?

EPO increases red blood cells, ARA-290 does not. According to a review, EPO's red cell effect runs through a receptor made of two EPO receptors, whereas the tissue-protective effect runs through a different receptor combination, which healthy tissues usually do not express but which injury or inflammation switches on [23].

According to the same review, the use of EPO for tissue protection is limited by the rise in haematocrit, platelet activation and a high risk of clots. ARA-290 is an 11-amino-acid peptide modelled on one part of EPO's structure that acts only on the tissue-protection receptor [23].

The difference for the reader: epoetins have EU marketing authorisations [3]regulator, extensive human evidence and well-described harms [2]official [14]A. The human studies of ARA-290 are described on its own page. On the WADA list EPO is in section S2.1.1, and section S2.1.5 prohibits innate repair receptor agonists, giving asialo EPO and carbamylated EPO as examples [5]regulator. The status of ARA-290 is described on its own page.

Epoetins and darbepoetin

The EU-wide marketing authorisations cover several epoetin alfa, beta, zeta and theta products as well as darbepoetin alfa (Aranesp) and methoxy polyethylene glycol-epoetin beta (Mircera) [3]regulator. WADA names darbepoetins, erythropoietins and EPO-based constructs in the same section S2.1.1 [5]regulator. Of the large trials described above, the diabetic kidney disease trial and the heart failure trial used darbepoetin [13, 20]A.

Combinations: EPO and iron

In treatment, the most important combination with EPO is iron. According to the product information, all other causes of anaemia, such as iron, folate or vitamin B12 deficiency, are investigated and treated before treatment, and adequate iron stores are ensured; iron is given if needed [2]official.

We found no controlled studies of other combinations in healthy people. General information: Peptides and the law in Finland.

Is EPO legal in Finland?

EPO products are prescription medicines in Finland. Epoetin alfa, epoetin zeta, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta are in annex 1 of the medicines list [4]regulator, and according to the EMA the medicine is available only on prescription [1]regulator.

• Marketing authorisations. In the EMA Article 57 data (as of 9 Oct 2026), epoetins, darbepoetin and methoxy polyethylene glycol-epoetin beta have EU-wide marketing authorisations that are also valid in Finland, for example Binocrit (epoetin alfa), Retacrit (epoetin zeta) and NeoRecormon (epoetin beta). There were no Finnish national authorisations in the same data [3]regulator. Article 57 shows the authorisation, not whether the product is available in pharmacies.
• Import and travel. General information: Peptides and the law in Finland and Travelling with peptides.

This is not legal advice. Disclaimer.

Is EPO doping?

Yes. On WADA's 2026 Prohibited List, erythropoietins are in class S2.1, and substances in class S2 are prohibited at all times, in and out of competition [5]regulator. Section S2.1.1 names darbepoetins, erythropoietins and methoxy polyethylene glycol-epoetin beta (CERA) as examples [5]regulator. The same classification is on the Finnish-language list of SUEK [6]regulator.

Detection is not certain. In the cyclist study, the sensitivity of two urine tests for detecting EPO use was 63.8% and 58.6%, and that of the biological passport based on blood values 91.3%. According to the authors, some users still evade detection [22]A.

Athletes can check the status of substances in the list of the Finnish Center for Integrity in Sports SUEK [6]regulator.

How is the quality of an EPO product assessed?

The quality of authorised epoetin is assessed as part of the marketing authorisation. For example, Binocrit (epoetin alfa) is a biosimilar whose structure, purity and biological activity were found to be highly similar to the reference medicine [1]regulator.

According to the product information, the product name and batch number are recorded in the patient file, and patients are switched from one product to another only under appropriate supervision [2]official.

We did not assess analyses of the content of unauthorised products for this page. A certificate of analysis (COA) does not show a product to be safe. More: How to read a COA and check a test result.

The future: what comes next?

For the anaemia of kidney disease, medicines taken by mouth have appeared alongside EPO injections. According to a Cochrane review, HIF stabilisers are now available for this purpose [24]A.

The review included 51 trials and 30,994 adults. Compared with EPO products, HIF stabilisers may have made little or no difference to cardiovascular deaths, heart attacks or strokes (low certainty evidence), and probably fewer transfusions were needed. Adverse events were reported rarely and inconsistently [24]A.

In sport, HIF activators such as daprodustat, roxadustat and vadadustat are prohibited in the same class as EPO (S2.1.2) [5]regulator.

FAQ

Read the research yourself: sources

Every source opens the original publication or the regulator's page. The level shows what the source itself reports.

1. European Medicines Agency. Binocrit (epoetin alfa): EPAR medicine overview and authorisation details (marketing authorisation issued 28 Aug 2007). EMA regulator
2. European Medicines Agency. Binocrit (epoetin alfa): EPAR product information, Annex I summary of product characteristics. Last updated 11 Jul 2025. EMA (PDF) official
3. European Medicines Agency. Article 57 product data (EMA/518502/2018, data as of 9 Oct 2026): epoetin, darbepoetin and methoxy polyethylene glycol-epoetin beta entries for Finland and the European Union. EMA regulator
4. Finland. Lääkeluettelo (Fimea medicines list), 230/2025, annex 1: epoetin alfa, epoetin zeta, darbepoetin alfa, methoxy polyethylene glycol-epoetin beta. Finlex regulator
5. World Anti-Doping Agency. 2026 Prohibited List, S2.1 Erythropoietins (EPO) and agents affecting erythropoiesis. wada-ama.org (PDF) regulator
6. Finnish Center for Integrity in Sports (SUEK). Doping substance groups and substances 2026, based on the WADA list: S2.1. SUEK regulator
7. Heuberger JAAC, Rotmans JI, Gal P, et al. Effects of erythropoietin on cycling performance of well trained cyclists: a double-blind, randomised, placebo-controlled trial. Lancet Haematol. 2017;4(8):e374-e386. PMID 28669689 A
8. Heuberger JA, Cohen Tervaert JM, Schepers FM, et al. Erythropoietin doping in cycling: lack of evidence for efficacy and a negative risk-benefit. Br J Clin Pharmacol. 2013;75(6):1406-1421. PMID 23216370 (review)
9. Thomsen JJ, Rentsch RL, Robach P, et al. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol. 2007;101(4):481-486. PMID 17668232 B
10. Sgrò P, Sansone M, Sansone A, Romanelli F, Di Luigi L. Effects of erythropoietin abuse on exercise performance. Phys Sportsmed. 2018;46(1):105-115. PMID 29113535 (review)
11. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085-2098. PMID 17108343 A
12. Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071-2084. PMID 17108342 A
13. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361(21):2019-2032. PMID 19880844 A
14. Palmer SC, Navaneethan SD, Craig JC, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153(1):23-33. PMID 20439566 A
15. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009;373(9674):1532-1542. PMID 19410717 A
16. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346(7):469-475. PMID 11844847 B
17. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009;40(12):e647-e656. PMID 19834012 A
18. Juul SE, Comstock BA, Wadhawan R, et al. A Randomized Trial of Erythropoietin for Neuroprotection in Preterm Infants. N Engl J Med. 2020;382(3):233-243. PMID 31940698 A
19. Brines ML, Ghezzi P, Keenan S, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A. 2000;97(19):10526-10531. PMID 10984541 C
20. Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210-1219. PMID 23473338 A
21. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med. 2007;357(10):965-976. PMID 17804841 A
22. Heuberger JAAC, van Eenoo P, Rotmans JI, et al. Sensitivity and specificity of detection methods for erythropoietin doping in cyclists. Drug Test Anal. 2019;11(9):1290-1301. PMID 31232530 A
23. Collino M, Thiemermann C, Cerami A, Brines M. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol Ther. 2015;151:32-40. PMID 25728128 (review)
24. Natale P, Palmer SC, Jaure A, et al. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022;8(8):CD013751. PMID 36005278 A
25. Breenfeldt Andersen A, Graae J, Bejder J, et al. Microdoses of Recombinant Human Erythropoietin Enhance Time Trial Performance in Trained Males and Females. Med Sci Sports Exerc. 2023;55(2):311-321. PMID 36317927 A
26. Najjar SS, Rao SV, Melloni C, et al. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA. 2011;305(18):1863-1872. PMID 21558517 A

Research sources (PubMed) and regulatory sources (EMA, Finlex, WADA, SUEK) read on 15 Oct 2026.

Evidence levels: A = randomised human trial or meta-analysis · B = observational human study or case series · C = animal study · D = cell or laboratory study · E = not peer-reviewed · regulator = a regulator's assessment or decision, not research evidence. The marker official means official product information (summary of product characteristics or label); it is not research evidence. For a review, the level shows what kind of research the statement rests on. No level: statements that something has not been studied, reviews' interpretations, named hypotheses and the general rules in our certificate-of-analysis guide.

Content is general information about research, not medical advice. If you have symptoms, contact a healthcare professional.